ImmuCell CorporationICCCNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +52.10% | +11.16% | +17.76% | -8.41% | -1.61% |
| Gross Profit Growth | +125.09% | +46.12% | +129.01% | +49.23% | +2.77% |
| EBITDA Growth | +0.00% | +495.12% | +0.00% | +403.01% | -50.60% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | -109.33% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | -653.68% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | -638.19% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | -638.19% |
| Weighted Average Shares Growth | +15.29% | +15.87% | +15.64% | +10.80% | +1.24% |
| Weighted Average Shares Diluted Growth | +15.29% | +15.87% | +15.64% | +10.80% | +1.24% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +276.06% | +175.28% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +257.54% | +207.05% | +0.00% | +0.00% |
| Receivables Growth | +74.42% | +29.75% | +22.79% | +11.44% | -100.00% |
| Inventory Growth | -8.95% | +2.91% | +13.63% | +31.39% | +30.29% |
| Asset Growth | +2.95% | +5.97% | +11.62% | +2.88% | -5.70% |
| Book Value per Share Growth | -4.50% | +1.57% | +10.12% | +1.84% | +0.00% |
| Debt Growth | -9.53% | -9.91% | -9.93% | -12.41% | -100.00% |
| R&D Expense Growth | -23.13% | -40.05% | -19.28% | -11.68% | -7.37% |
| SG&A Expenses Growth | +16.39% | +11.00% | -10.72% | +20.14% | +58.82% |